Description
O-304 Capsules | Pan-AMPK Activator — Metabolic Research
O-304 (also designated ATX-304 and OS-01) is a first-in-class, orally bioavailable pan-AMPK activator — meaning it activates all 12 AMPK heterotrimer complexes, unlike earlier allosteric activators (e.g., A-769662) that show complex selectivity. Clinical Phase I/II data demonstrate improvements in insulin sensitivity, fatty acid oxidation, and glucose uptake without the risk of hypoglycaemia. These capsules (150mg per capsule, 30 capsules) are formulated for research protocols examining whole-body metabolic activation.
Mechanism of Action
- Pan-AMPK activation — binds the ADaM site on all 12 AMPK heterotrimeric complexes (α1/2 × β1/2 × γ1/2/3)
- Insulin sensitisation — independent of insulin receptor; activates GLUT4 trafficking and glucose uptake in muscle and adipose
- Fatty acid oxidation — inhibits ACC (acetyl-CoA carboxylase), reducing malonyl-CoA and derepressing CPT1-mediated beta-oxidation
- Mitochondrial biogenesis — activates PGC-1α transcriptional program via SIRT1/SIRT3 phosphorylation
Research Areas
O-304 is studied in type 2 diabetes, AMPK biology, fatty liver disease, exercise physiology, and longevity research. Mechanistically distinct from and complementary to AICAR (indirect AMPK activation) and MOTS-c capsules (mitochondrial AMPK signaling).
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. L. Bhardwaj –
O-304 capsules for our oral AMPK activator and type 2 diabetes model research. Content purity >99% by HPLC. AMPK phosphorylation in our hepatocyte model showed expected dose-dependent activation. COA excellent.
A. Svensson –
150mg O-304 capsules — convenient oral format for our AMP-kinase research. Content confirmed. COA thorough. Our glucose uptake model showed robust AMPK-mediated response. Fast delivery.
L. Osei –
Good O-304 capsules. Content >98.5%. Capsule uniformity within spec. COA comprehensive. Practical oral format for our AMPK signaling and metabolic disease research.